A Look At PropThink’s Top Stories This Week
Most Popular - Between Keryx and its Japanese partner JT Torii, four clinical trials for lead candidate Zerenex are set to report data over the coming months. The … Continue Reading
Read NowRecap
A Recap of PropThink’s Week in Biotech
Most Popular - We offered some insight this week into how social media can drive the markets. Jason Napodano noted recent performance from SRPT, and discussed what patient-investor … Continue Reading
Read NowPropThink’s Weekly Healthcare Wrap-Up
Most Popular - Pharmacyclics warned in its 3Q earnings release that employees might sell market-moving amounts of shares on Wednesday as they exercised options. As we expected, shares … Continue Reading
Read NowWeekly Recap: PropThink’s Latest in Healthcare and Biotech
Most Popular - Gilead paid a lot of money – $11B to be exact – to acquire Pharmasset back in 2011. Was it worth it? Propthink dug in … Continue Reading
Read NowPropThink’s Healthcare and Biotech Roundup
Most Popular - Our earnings preview supposed that in-line QCOR earnings could improve share price. QCOR delivered well-above estimates, but shares remained flat following, as reimbursement concerns still linger. … Continue Reading
Read NowA Recap of this Week’s Top Stories in Healthcare
Most Popular - PropThink published its latest report on Keryx Biopharmaceuticals last week, and on Monday we followed up with some technical discussion. We also included QCOR in … Continue Reading
Read NowPropThink’s Weekly Wrap-Up
Recap - A patent extension for Folotyn added five years to the drug’s market exclusivity and elicited a rally in Spectrum (SPPI) on Monday, but the news … Continue Reading
Read Now